Kraig Biocraft Laboratories Inc. has announced the commencement of production for its BAM-1 recombinant spider silk hybrids, ahead of the originally planned July schedule due to successful production trials. This production phase is pivotal for Kraig Labs as it advances toward commercializing sustainable and cost-effective spider silk.

This cycle marks the first true production hybrids transition into the manufacturing environment for the Company and represents a more than 10-fold increase in production compared to spring trials. It also stands as the largest single batch of spider silk production in the Company's history.

These hybrids were developed by incorporating Kraig Labs’ Dragon Silk™ recombinant spider silk technology into two commercial silkworm strains. The resulting BAM-1 hybrids feature the largest cocoons and most resilient silkworms the Company has produced, leading to higher silk yields and improved production efficiency while maintaining fiber material performance.

“This successful launch of the BAM-1 hybrids is the culmination of over a year of dedicated development by our team. The spring production trials confirmed that we have the right team, technology, and facilities to make 2024 a breakthrough year for spider silk commercialization,” said Kraig Labs’ Founder and CEO, Kim Thompson. “This cycle solidifies our path to achieving our initial production milestone of a metric ton of spider silk.”